In 2021, researchers investigated the effects of Nicotinamide mononucleotide on muscle insulin sensitivity in women with prediabetes.
Summary of results:
The study shows that NMN supplementation elevates NAD+ levels in blood cells and enhances muscle insulin sensitivity and structure in older, pre-diabetic women. This clinical trial is the first to demonstrate NMN’s positive impact on human health. Additionally, NMN increased the expression of platelet-derived growth factor receptor β and other genes associated with muscle remodeling.
Summary of the research:
In rodents, obesity and aging lead to a decrease in the production of nicotinamide adenine dinucleotide (NAD+), resulting in metabolic disorders. Nicotinamide mononucleotide (NMN) is a limiting factor in NAD+ biosynthesis in mammals. Therefore, we conducted a randomized, placebo-controlled, double-blind study lasting 10 weeks to examine the effect of NMN supplementation on metabolic function in postmenopausal women with prediabetes who were overweight or obese. After NMN supplementation, insulin-stimulated glucose processing, measured using the hyperinsulinemic-euglycemic clamp, and insulin signaling in skeletal muscles (phosphorylation of protein kinase AKT and mechanistic target of rapamycin (mTOR)) improved, while no changes were observed after placebo treatment. NMN supplementation led to an increase in the expression of platelet-derived growth factor receptor β and other genes involved in muscle remodeling. These findings demonstrate that NMN can improve muscle insulin sensitivity, insulin signaling, and remodeling in postmenopausal women with prediabetes who are overweight or obese (clinicaltrial.gov NCT03151239).
Source: https://pubmed.ncbi.nlm.nih.gov/33888596/
